After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

11/12/2014 - 2 minutes

iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to Pfizer rights to iTeos’ pre-clinical compounds targeting the enzymes expressed in many cancers. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. It completes a previous deal with Merck a few weeks ago. 

Additionally, the parties will collaborate to discover and validate new targets that play key roles in the ability of tumors to evade immune responses. These new targets will be shared by iTeos and Pfizer for further independent or collaborative development.

iTeos will receive from Pfizer an up-front payment of € 24 million, plus an equity investment, licensing fees and collaborative funding. Further, iTeos will be eligible to earn potential milestone payments from Pfizer based on the achievement of specific development, regulatory and commercial milestones across the IDO1 and TDO2 programs, in addition to royalties on sales.

Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2) are enzymes that break down the amino acid tryptophan. 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: